Director at Indivior (INDV) makes open‑market purchase of 940 shares

Rhea-AI Filing Summary

Indivior Pharmaceuticals, Inc. director Stuart A. Kingsley bought additional shares of the company in the open market. On March 6, 2026, he purchased 940 shares of Common Stock at an average price of $31.865 per share. Following this open‑market purchase, he directly owns 5,582 shares of Indivior common stock.

Insider Trade Summary

Net Buyer: 940 shares ($29,953)

Net Buy 1 txn

Insider Kingsley Stuart A

Role Director

Bought 940 shs ($30K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	940	$31.865	$30K

Holdings After Transaction: Common Stock — 5,582 shares (Direct)

Footnotes (1)

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kingsley Stuart A

(Last) (First) (Middle)

10710 MIDLOTHIAN TURNPIKE

SUITE 125

(Street)

NORTH CHESTERFIELD VA 23235

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Indivior Pharmaceuticals, Inc. [ INDV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
03/06/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/06/2026		P		940	A	$31.865	5,582	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

	/s/Alice Givens, Power of Attorney	03/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Indivior (INDV) report for Stuart A. Kingsley?

Indivior reported that director Stuart A. Kingsley made an open‑market purchase of 940 shares of Common Stock. The transaction took place on March 6, 2026, and was recorded as a direct ownership increase.

At what price did the Indivior (INDV) director buy shares in this Form 4?

The director bought 940 Indivior Common Stock shares at an average price of $31.865 per share. This was classified as an open‑market purchase, indicating he paid prevailing market prices rather than receiving shares as compensation.

How many Indivior (INDV) shares does Stuart A. Kingsley hold after the transaction?

After the reported transaction, Stuart A. Kingsley directly owns 5,582 shares of Indivior Common Stock. This total reflects his position immediately following the open‑market purchase of 940 shares disclosed in the Form 4.

Is the Indivior (INDV) Form 4 transaction a buy or a sell?

The Form 4 shows a buy transaction. Stuart A. Kingsley executed an open‑market purchase of 940 shares of Indivior Common Stock, increasing his directly held position rather than disposing of shares.

What type of security was involved in the latest Indivior (INDV) insider trade?

The transaction involved Common Stock of Indivior Pharmaceuticals, Inc. It was a non‑derivative transaction, meaning no options or other derivatives were exercised or converted as part of this reported insider activity.